GlassScriptPhysician profile
Tyrah Hickman
NPI 1932735727
$5,108.18
in general payments reported to CMS, 2019-2025
23 companies · $925 in 2025
The $925 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $486 · 2022: $795 · 2023: $1,036 · 2024: $1,866 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,800 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,799.96 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $851.58 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Vanda Pharmaceuticals INC. | $539.24 | 2021-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $535.32 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $473.83 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $429.99 | 2021-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $330.59 | 2021-2024 | |
| Axsome Therapeutics, INC. | $319.50 | 2023-2025 | Auvelity |
| Gilead Sciences, INC. | $250.00 | 2024-2025 | Biktarvy |
| Indivior INC. | $191.55 | 2022-2024 | Perseris |
| Avanir Pharmaceuticals, INC. | $145.07 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $140.13 | 2024 | Cobenfy |
| Novo Nordisk INC | $131.80 | 2024 | Wegovy |
| Alexion Pharmaceuticals, INC. | $129.74 | 2024 | |
| Astellas Pharma Global Development | $129.60 | 2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2024 | Farxiga |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $123.12 | 2024 | Qelbree |
| Kyowa Kirin, INC. | $86.73 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $51.89 | 2022-2023 | Uzedy |
| Viiv Healthcare Company | $41.66 | 2025 | Apretude |
| Takeda Pharmaceuticals U.S.A., INC. | $29.43 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.69 | 2021 | |
| Merck Sharp & Dohme LLC | $18.03 | 2025 | Pifeltro |
| Sunovion Pharmaceuticals INC. | $15.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyrah Hickman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.